Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Adjuvant chemotherapy for invasive bladder cancer. Multicenter study].

I Fukui1, S Gotoh, K Kihara

  • 1Department of Urology, Tokyo Medical and Dental University School of Medicine.

Nihon Hinyokika Gakkai Zasshi. the Japanese Journal of Urology
|October 1, 1992
PubMed
Summary

Adjuvant chemotherapy for invasive bladder cancer improved survival, with at least three cycles showing better outcomes. Immunopotentiators and Kampo medicine did not significantly impact prognosis in this study.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Isotropy of Cosmic Rays beyond 10^{20}  eV Favors Their Heavy Mass Composition.

Physical review letters·2024
Same author

An extremely energetic cosmic ray observed by a surface detector array.

Science (New York, N.Y.)·2023
Same author

Glibenclamide attenuates brain edema associated with microglia activation after intracerebral hemorrhage.

Neuro-Chirurgie·2022
Same author

Intestinal cancer progression by mutant p53 through the acquisition of invasiveness associated with complex glandular formation.

Oncogene·2017
Same author

TNF-α/TNFR1 signaling promotes gastric tumorigenesis through induction of Noxo1 and Gna14 in tumor cells.

Oncogene·2013
Same author

Inflammation-induced repression of tumor suppressor miR-7 in gastric tumor cells.

Oncogene·2011

Area of Science:

  • Oncology
  • Urology
  • Clinical Cancer Research

Background:

  • Invasive bladder cancer necessitates aggressive treatment strategies.
  • Adjuvant chemotherapy following radical surgery is a common approach.
  • The role of immunomodulators and traditional medicine in cancer treatment requires further investigation.

Purpose of the Study:

  • To evaluate the efficacy of adjuvant combination chemotherapy in patients with invasive bladder cancer.
  • To assess the impact of immunopotentiator (OK-432) and Kampo medicine (Juzentaihoto: TJ-48) on patient survival.
  • To identify prognostic factors influencing survival in bladder cancer patients undergoing cystectomy and chemotherapy.

Main Methods:

  • Prospective study of 50 patients with invasive bladder cancer (pT2-4, pN0-2, M0) treated with total cystectomy and adjuvant chemotherapy.

Related Experiment Videos

  • Randomized administration of OK-432 or TJ-48 to a subset of patients.
  • Analysis of survival rates based on tumor grade, stage, chemotherapy cycles, and adjuvant agents.

    • Main Results:

    • 3- and 5-year survival rates were 71% and 67% for 48 evaluable patients.
    • Histologic grade (grade 2 vs. grade 3) and number of chemotherapy cycles (≥3 vs. ≤2) significantly correlated with survival.
    • OK-432, TJ-48, pre-operative irradiation, and intra-arterial chemotherapy did not show a favorable effect on survival.
    • Adjuvant chemotherapy was generally well-tolerated, with over 70% completing at least 3 cycles.

    Conclusions:

    • Adjuvant chemotherapy, particularly with 3 or more cycles, is crucial for improving survival in invasive bladder cancer post-cystectomy.
    • Immunopotentiators and Kampo medicine did not demonstrate a significant benefit in this patient cohort.
    • Histologic grade and adequate chemotherapy dosage are key determinants of patient prognosis.